$CRSP News Article - CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
https://marketwirenews.com/news-releases/cris...58180.html